Camurus: Advancing Patient Care Through Innovation with FluidCrystal®
Drug delivery for incretins refers to how medications that mimic or enhance the activity of incretin hormones—primarily GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)—are formulated and administered to achieve optimal therapeutic effect. These drugs are primarily used in type 2 diabetes and obesity treatment. 🧬 What Are Incretins?Incretins are hormones released by the gut […]
The Quantum Power of GLP-1 Peptides: Unlocking the Science that Leads to Lasting Weight Loss and Optimal Healthspan Paperback – June 3, 2025
by William A Seeds MD (Author) ($36.00) In The Quantum Power of GLP-1 Peptides: Unlocking the Science that Leads to Lasting Weight Loss and Optimal Healthspan, Dr. William A.Seeds uncovers the cellular mechanisms behind GLP-1s and other peptides that can help people lose significant weight and treat type-2 diabetes. Importantly, Dr. Seeds has also gathered peer-reviewed research that shows […]
Muscle mass loss during GLP1 receptor agonist therapy prevented with GDF8 and activin A blockade
Post Content
Eli Lilly inks deal with Camurus for its long-acting obesity tech
Eli Lilly has tapped Camurus in a deal worth up to $870 million for its drug delivery technology to develop four long-acting incretin candidates. The technology can be used on any of Lilly’s dual GLP …
State-dependent central synaptic regulation by GLP-1 is essential for energy homeostasis
Nature Metabolism, Published online: 04 June 2025; doi:10.1038/s42255-025-01305-x In this paper, the authors describe the energy state-dependent regulation of the PVNGLP-1R to DVC circuit, resulting in altered food intake and metabolic health, mediated by GLP-1 receptor signalling.
Advisory: Nutrition Priorities for GLP-1 Use in Obesity
Four clinical organizations jointly release an advisory with evidence-based nutrition and lifestyle interventions to enhance GLP-1 treatment outcomes for obesity. Medscape Medical News
Prediction: Eli Lilly Will Reach a $1 Trillion Valuation by 2027
Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare company in the world, with a market cap of more than $650 billion. But there’s still much more growth on the horizon for the business in the years ahead. Although as of this week the […]
Teen Wegovy prescriptions surge 50% in 1 year: Report
New prescriptions for Wegovy among teenagers increased by 50% between 2023 and 2024, according to a June 3 report from healthcare data company Truveta. To analyze GLP-1 utilization trends among adolescents, Truveta examined data from 1.2 million children aged 12 to 17 who had a recorded body mass index the same day as an outpatient […]
Regeneron boosts obesity pipeline with Hansoh’s GLP-1/GIP for $2B
Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual glucagon-like peptide 1 (GLP-1)/gastric inhibitory polypeptide (GIP) receptor agonist, HS-20094, for up to $2 billion.
Weight loss drugs like Ozempic can mess with your fertility, dietitian warns — how it can impact both men and women
Registered dietitian Ayla Barmmer told The Post that about 15% of her patients taking GLP-1 medications have struggled to conceive.